Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases

Forster M, Kury P, Aktas O, Warnke C, Havla J, Hohlfeld R, et al. Managing risks with immune therapies in multiple sclerosis. Drug Saf. 2019;42(5):633–47. https://doi.org/10.1007/s40264-018-0782-8.

CAS  Article  PubMed  Google Scholar 

Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7(3):165–72. https://doi.org/10.1038/nrneurol.2011.1.

CAS  Article  PubMed  Google Scholar 

Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 Pt 1):859–66. https://doi.org/10.1111/j.1600-6143.2006.01288.x.

CAS  Article  PubMed  Google Scholar 

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320–7. https://doi.org/10.1001/jamaneurol.2017.4011.

Article  PubMed  PubMed Central  Google Scholar 

Wendler J, Burmester GR, Sorensen H, Krause A, Richter C, Tony HP, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014;16(2):R80. https://doi.org/10.1186/ar4521.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135–41. https://doi.org/10.1016/j.jaut.2014.03.002.

CAS  Article  PubMed  Google Scholar 

Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE. 2018;13(5):e0197415. https://doi.org/10.1371/journal.pone.0197415.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Dos Santos A, Noury JB, Genestet S, Nadaj-Pakleza A, Cassereau J, Baron C, et al. efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020;27(11):2277–85. https://doi.org/10.1111/ene.14391.

CAS  Article  PubMed  Google Scholar 

Alcala C, Gascon F, Perez-Miralles F, Gil-Perotin S, Navarre A, Bosca I, et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265(7):1690–7. https://doi.org/10.1007/s00415-018-8899-3.

CAS  Article  PubMed  Google Scholar 

Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342–8. https://doi.org/10.1001/jamaneurol.2016.1637.

Article  PubMed  Google Scholar 

Barra ME, Soni D, Vo KH, Chitnis T, Stankiewicz JM. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016;2:2055217316672100. https://doi.org/10.1177/2055217316672100.

Article  PubMed  PubMed Central  Google Scholar 

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154.

CAS  Article  PubMed  Google Scholar 

Benkirane R, Soulaymani-Bencheikh R, Khattabi A, Benabdallah G, Alj L, Sefiani H, et al. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Saf. 2015;38(4):383–93. https://doi.org/10.1007/s40264-014-0257-5.

CAS  Article  PubMed  Google Scholar 

Gautron S, Wentzell J, Kanji S, Nguyen T, Kobewka DM, MacDonald E. Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting. Can J Hosp Pharm. 2018;71(5):316–23.

PubMed  PubMed Central  Google Scholar 

Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, et al. efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019;18(5):542–8. https://doi.org/10.1016/j.autrev.2019.03.011.

CAS  Article  PubMed  Google Scholar 

Shaygannejad V, Fayyazi E, Badihian S, Mirmosayyeb O, Manouchehri N, Ashtari F, et al. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol. 2019;266(3):642–50. https://doi.org/10.1007/s00415-019-09180-9.

CAS  Article  PubMed  Google Scholar 

Mugosa S, Djordjevic N, Djukanovic N, Protic D, Bukumiric Z, Radosavljevic I, et al. Factors affecting the development of adverse drug reactions to beta-blockers in hospitalized cardiac patient population. Patient Prefer Adherence. 2016;10:1461–9. https://doi.org/10.2147/PPA.S108579.

Article  PubMed  PubMed Central  Google Scholar 

D’Arena G, Simeon V, Laurenti L, Cimminiello M, Innocenti I, Gilio M, et al. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633–41. https://doi.org/10.1080/104.281942017.1306648.

Article  PubMed  Google Scholar 

Bourdette D, Yadav V. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep. 2008;8(5):417–8. https://doi.org/10.1007/s11910-008-0064-4.

Article  PubMed  Google Scholar 

Naser Moghadasi A, Darki A, Masoumi P, Hashemi SN, Ghadiri F. Evaluating the efficacy and safety of Zytux(TM) (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. Mult Scler Relat Disord. 2019;36:101419. https://doi.org/10.1016/j.msard.2019.101419.

Article  PubMed  Google Scholar 

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–91. https://doi.org/10.1001/jamaneurol.2019.3365.

Article  PubMed  Google Scholar 

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. https://doi.org/10.1056/NEJMoa011795.

CAS  Article  PubMed  Google Scholar 

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91. https://doi.org/10.1016/S1470-2045(06)70664-7.

CAS  Article  PubMed  Google Scholar 

Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. J Dtsch Dermatol Ges. 2010;8(6):411. https://doi.org/10.1111/j.1610-0387.2010.07339.x.

Article  PubMed  Google Scholar 

Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K. Malignancies after rituximab treatment: just coincidence or more? J BUON. 2011;16(1):112–5.

CAS  PubMed  Google Scholar 

Schrezenmeier E, Budde K, Staeck O, Lehner L, Duerr M, Khadzhynov D, et al. Incidence of infectious disease and malignancies after rituximab therapy in kidney transplant recipients: results from a cohort in Germany. Transplant Proc. 2017;49(10):2269-73. https://doi.org/10.1016/j.transproceed.2017.09.042.

Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005;116(4):900–5. https://doi.org/10.1016/j.jaci.2005.03.028.

CAS  Article  PubMed  Google Scholar 

Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, et al. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(6):1148–52. https://doi.org/10.1093/rheumatology/keq436.

CAS  Article  Google Scholar 

Covelli M, Sarzi-Puttini P, Atzeni F, Macchioni P. Safety of rituximab in rheumatoid arthritis. Reumatismo. 2010;62(2):101–6. https://doi.org/10.4081/reumatismo.2010.101.

CAS  Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif